Oticon Zeal vs Otofonix Groove

The Oticon Zeal is a premium invisible-in-ear prescription hearing aid priced at $4,798. In HearAdvisor's lab testing, it earned an A grade with a SoundScore of 4.7/5, placing it in the top 11% of prescription hearing aids tested and ranking #5 of 36 devices in its category. Speech performance is where the Zeal truly excels. It achieved an excellent 4.9/5 in speech-in-quiet testing, scoring 1.56 points above the category average—among the strongest results we've measured. Speech-in-noise performance is solid at 3.0/5, which is 1.08 points above the category average of 1.96/5, making it notably better than typical prescription aids in challenging listening environments. Music streaming quality scores 3.3/5, sitting 0.66 points above category average and providing solid fidelity for phone audio. However, the Zeal shows some limitations in other areas. Own-voice comfort is mixed at 2.0/5, falling 0.75 points below the category average—users sensitive to how their own voice sounds may notice this. Feedback handling, while solid in absolute terms at 3.3/5, measures 1.41 points below the category average of 4.71/5. The Zeal is best suited for users who prioritize outstanding speech clarity in both quiet and moderately noisy settings, and who value quality audio streaming. Those particularly sensitive to own-voice perception or who need maximum feedback stability may want to discuss these tradeoffs with their hearing care provider.

The Otofonix Groove is a behind-the-ear prescription hearing aid priced at $795, earning a C grade with a SoundScore of 2.7/5 in our lab testing. This rechargeable BTE device ranks 36th out of 36 tested prescription hearing aids, placing it in the bottom tier of its category. In our testing, the Groove demonstrated one clear strength: excellent feedback handling at 5.0/5, scoring 0.29 points above the category average. The device remained stable during our standardized challenge motions with no audible feedback issues. However, speech performance was significantly limited, with both speech in quiet and speech in noise scoring 1.0/5—falling 2.32 and 0.96 points below their respective category averages. Music streaming quality scored 0.0/5, which is 2.64 points below the prescription category average. Own-voice comfort was also low at 0.4/5 in the tuned configuration, 2.35 points below average, suggesting notable occlusion-related concerns. The normalized Initial Score of 2.7/5 and Tuned Score of 2.6/5 indicate that professional fitting adjustments did not improve overall performance. Given its positioning at the bottom of the prescription hearing aid category and the availability of lower-priced alternatives that scored higher in our testing, the Otofonix Groove may be difficult to recommend for most users seeking balanced sound quality across listening situations.